BCL2L1 and neoplasm: This can be achieved pharmacologically by applying PROTACs that target BCL-XL for ubiquitination (and thereby for proteasome-mediated degradation) within the tumor microenvironment, but these PROTACs cannot eliminate platelets because the expression of VHL or CRBN in platelets is minimal16,18.